R1	Has_value Arg1:T4 Arg2:T5	
*	OR T2 T3
R2	Has_qualifier Arg1:T6 Arg2:T7	
R3	Has_multiplier Arg1:T8 Arg2:T9	
R4	Has_temporal Arg1:T8 Arg2:T10	
R5	Has_temporal Arg1:T6 Arg2:T8	
T1	Informed_consent 0 109	Subjects must be capable of providing signed and dated written informed consent by date of Visit 0 (-2 week).
T2	Person 111 115	Male
T3	Person 120 126	female
T4	Person 127 131	aged
T5	Value 132 150	=19 and < 65 years
T6	Condition 175 188	schizophrenia
T7	Qualifier 203 330	Diagnostic and Statistical Manual of Mental Disorders, 4th edition text revision or 5th edition (DSM-<U+2163>-TR or 5) criteria
T8	Temporal 338 356	history of illness
T9	Multiplier 357 381	for at least for 3 years
T10	Temporal 382 400	prior to screening
T11	Drug 421 449	atypical antipsychotic drugs
T12	Non-representable 451 600	and should be maintained on current antipsychotic drugs (including atypical antipsychotic drugs) and dose for at least 4 weeks prior to the screening
T13	Non-representable 603 775	Subjects who need antipsychotic treatment (other than clozapine), and would be stable when switching to long-acting injectable aripiprazole in the investigator's judgement.
T14	Post-eligibility 777 911	Subjects must exhibit willingness, physiologic capability, and an educational level sufficient to comply with all protocol procedures.
